Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMR7H2V)

Drug Name
PRX-08066 Drug Info
Synonyms
PRX-08066; 866206-54-4; PRX-08066 free base; UNII-82SK298EBU; PRX 08066; CHEMBL513994; 82SK298EBU; 5-((4-(6-chlorothieno[2,3-d]pyrimidin-4-ylamino)piperidin-1-yl)methyl)-2-fluorobenzonitrile; SCHEMBL1604039; DTXSID60235710; IENZFHBNCRQMNP-UHFFFAOYSA-N; BCP14768; BDBM50249180; ZINC40403513; AKOS030526950; QC-5875; CS-0991; SB16508; 5-((4-(6-Chlorothieno(2,3-d)pyrimidine-4-ylamino)piperidin-1-yl)methyl)-2-fluorobenzonitrile; PRX 08066;PRX08066; NCGC00386238-02; AK548029; HY-15472; Benzonitrile, 5-((4-((6-chlorothieno(2,3-d)pyrimidi
Indication
Disease Entry ICD 11 Status REF
Pulmonary arterial hypertension BB01.0 Phase 2 [1]
Cross-matching ID
PubChem CID
11502243
CAS Number
CAS 866206-54-4
TTD Drug ID
DMR7H2V

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Patented Agent(s)
Download the Complete Related Drug List
Drug(s) Targeting 5-HT 2B receptor (HTR2B)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Metergolin DMJFP6G Hyperprolactinaemia 5A60.1 Approved [2]
Triflupromazine DMKFQJP Psychotic disorder 6A20-6A25 Approved [3]
Minaprine DM0EP7M Depression 6A70-6A7Z Approved [4]
SPN-812 DMTV7XH Attention deficit hyperactivity disorder 6A05.Z Phase 4 [5]
Vabicaserin DM9GZW6 Psychotic disorder 6A20-6A25 Phase 2 [6]
Pyrimidine derivative 29 DMVOYJ8 N. A. N. A. Patented [7]
Pyrimidine derivative 26 DM90WKN N. A. N. A. Patented [7]
Pyrimidine derivative 23 DM5MLQU N. A. N. A. Patented [7]
Pyrimidine derivative 25 DM51MFS N. A. N. A. Patented [7]
Pyrimidine derivative 27 DMIQSDW N. A. N. A. Patented [7]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
5-HT 2B receptor (HTR2B) TT0K1SC 5HT2B_HUMAN Antagonist [1]

References

1 Emerging treatments for pulmonary arterial hypertension. Expert Opin Emerg Drugs. 2006 Nov;11(4):609-19.
2 Pharmacological characterisation of the agonist radioligand binding site of 5-HT(2A), 5-HT(2B) and 5-HT(2C) receptors. Naunyn Schmiedebergs Arch Pharmacol. 2004 Aug;370(2):114-23.
3 Some properties of 5-hydroxytryptamine receptors in the hindquarters of the rat. Br J Pharmacol. 1979 Sep;67(1):79-85.
4 Privileged structures: a useful concept for the rational design of new lead drug candidates. Mini Rev Med Chem. 2007 Nov;7(11):1108-19.
5 New Insights into the Mechanism of Action of Viloxazine: Serotonin and Norepinephrine Modulating Properties. J Exp Pharmacol. 2020 Aug 25;12:285-300.
6 Prediction of Efficacy of Vabicaserin, a 5-HT2C Agonist, for the Treatment of Schizophrenia Using a Quantitative Systems Pharmacology Model.CPT Pharmacometrics Syst Pharmacol.2014 Apr 23;3:e111.
7 Novel serotonin receptor 2 (5-HT2R) agonists and antagonists: a patent review (2004-2014).Expert Opin Ther Pat. 2016;26(1):89-106.